JP5809054B2 - 可溶性組換えインフルエンザ抗原 - Google Patents
可溶性組換えインフルエンザ抗原 Download PDFInfo
- Publication number
- JP5809054B2 JP5809054B2 JP2011516935A JP2011516935A JP5809054B2 JP 5809054 B2 JP5809054 B2 JP 5809054B2 JP 2011516935 A JP2011516935 A JP 2011516935A JP 2011516935 A JP2011516935 A JP 2011516935A JP 5809054 B2 JP5809054 B2 JP 5809054B2
- Authority
- JP
- Japan
- Prior art keywords
- rha
- nucleic acid
- plant
- peptide
- hemagglutinin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022000 influenza Diseases 0.000 title description 23
- 239000000427 antigen Substances 0.000 title description 16
- 108091007433 antigens Proteins 0.000 title description 16
- 102000036639 antigens Human genes 0.000 title description 16
- 101710154606 Hemagglutinin Proteins 0.000 claims description 137
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 137
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 137
- 101710176177 Protein A56 Proteins 0.000 claims description 137
- 239000000185 hemagglutinin Substances 0.000 claims description 129
- 241000196324 Embryophyta Species 0.000 claims description 89
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 58
- 239000002773 nucleotide Substances 0.000 claims description 57
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 44
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 42
- 238000006384 oligomerization reaction Methods 0.000 claims description 41
- 230000014759 maintenance of location Effects 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 20
- 230000001052 transient effect Effects 0.000 claims description 12
- 240000008042 Zea mays Species 0.000 claims description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 11
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 9
- 229920002494 Zein Polymers 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 235000009973 maize Nutrition 0.000 claims description 9
- 239000005019 zein Substances 0.000 claims description 9
- 229940093612 zein Drugs 0.000 claims description 9
- 102000009123 Fibrin Human genes 0.000 claims description 7
- 108010073385 Fibrin Proteins 0.000 claims description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 7
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 claims description 7
- 229950003499 fibrin Drugs 0.000 claims description 7
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 claims description 6
- 241000701533 Escherichia virus T4 Species 0.000 claims description 6
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical group [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 description 92
- 235000018102 proteins Nutrition 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 49
- 230000001105 regulatory effect Effects 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 35
- 239000000284 extract Substances 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 125000003275 alpha amino acid group Chemical group 0.000 description 26
- 239000002028 Biomass Substances 0.000 description 24
- 241000700605 Viruses Species 0.000 description 23
- 239000012634 fragment Substances 0.000 description 23
- 239000013638 trimer Substances 0.000 description 20
- 230000004927 fusion Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 244000061176 Nicotiana tabacum Species 0.000 description 17
- 239000000419 plant extract Substances 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 241000712461 unidentified influenza virus Species 0.000 description 14
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 13
- 210000005220 cytoplasmic tail Anatomy 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 238000005829 trimerization reaction Methods 0.000 description 11
- 102000005348 Neuraminidase Human genes 0.000 description 10
- 108010006232 Neuraminidase Proteins 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 241000589158 Agrobacterium Species 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000219823 Medicago Species 0.000 description 8
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000010474 transient expression Effects 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229960003971 influenza vaccine Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108090000051 Plastocyanin Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 3
- 102000004405 Collectins Human genes 0.000 description 3
- 108090000909 Collectins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000207746 Nicotiana benthamiana Species 0.000 description 3
- 229920000037 Polyproline Polymers 0.000 description 3
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 108010058731 nopaline synthase Proteins 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WOJJIRYPFAZEPF-YFKPBYRVSA-N 2-[[(2s)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CN WOJJIRYPFAZEPF-YFKPBYRVSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010025915 Nitrite Reductases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100024554 Tetranectin Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 108010086192 chymostatin Proteins 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108010026466 polyproline Proteins 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 101150089406 prd gene Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010013645 tetranectin Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- INOZZBHURUDQQR-AJNGGQMLSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 INOZZBHURUDQQR-AJNGGQMLSA-N 0.000 description 1
- BKWMKTIGFLPGOV-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO BKWMKTIGFLPGOV-RABCQHRBSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 101710197633 Actin-1 Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 101500006437 Arabidopsis thaliana Ubiquitin Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 101100184662 Caenorhabditis elegans mogs-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 101710138460 Leaf protein Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101001072198 Mus musculus Protein disulfide-isomerase Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150005851 NOS gene Proteins 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000723762 Potato virus Y Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 108010000614 SEKDEL sequence Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229940027138 cambia Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 108010041601 histidyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
これらおよび本発明の他の特色は、添付の図面を参照する以下の説明からより明らかになるだろう。
本発明を例示する選択されたHAは、インフルエンザ株A/ニューカレドニア/20/99(H1N1)から得られた。A/ニューカレドニア/20/99 HAはよく特徴づけられており、免疫検出ツールは商業的に入手可能である。すべてのHAの三次元構造がよく保存されるので、本発現ストラテジーは直接他のHAに適用することができる。
1.PDIシグナルペプチドを持ち、膜貫通領域を含む全長rHA(配列番号:9);
2.項目1のrHAから膜貫通領域および細胞質尾部を除去し、保留シグナルSEKDELによって置換した(配列番号:10);
3.項目1のrHAから膜貫通領域および細胞質尾部を除去し、保留シグナルHDELによって置換した(配列番号:11);
4.項目1のrHAから膜貫通領域および細胞質尾部を除去した(配列番号:12);
5.項目1のrHAから膜貫通領域および細胞質尾部を除去し、GCN4−pIIによって置換した(配列番号:13);
6.項目1のrHAから膜貫通領域および細胞質尾部を除去し、GCN4−pIIによって置換し、C末端でSEKDEL保留シグナルを持つ(配列番号:14);
7.項目1のrHAから膜貫通領域および細胞質尾部を除去し、PRDドメインによって置換した(配列番号:15);および
8.項目1のrHAから膜貫通領域および細胞質尾部を除去し、PRDドメインによって置換し、C末端でSEKDEL保留シグナルを持つ(配列番号:16)。
実施例1中に記載された8つの異なる遺伝子コンストラクトを合成した。インフルエンザ株A/ニューカレドニア/20/99からのHAの野生型ヌクレオチド配列は、制限部位を挿入または除去するためにのみ修飾して、クローニング工程を促進した。遺伝子配列中でこれらの小さな修飾は、生じたタンパク質のアミノ酸配列を変化させなかった。HA0遺伝子はPDIシグナルペプチドのATGと同調して5’末端にApaI制限部位を持って合成された。7個の他の遺伝子は5’末端にKpnI制限部位を持つ。すべての遺伝子は終止コドン(TAA)により3’末端で終了し、SacIおよびStuI制限部位が続く。デザインされたクローニングストラテジーに従って、以下の制限部位は最終的なプラスミド中で唯一であるようにデザインされた。ApaI、BstZ17I、SacI、KpnI、BglII、およびStuI。異なる遺伝子断片を植物バイオテクノロジー研究所(Plant Biotechnology Institute)で合成し、pUC18の中へクローン化し導入した。選択されたヌクレオチド配列情報は図6中で与えられる(配列番号:17〜24)。
様々なDNAコンストラクションは公知の組換えDNA技術を使用して組み立てられた。(Sambrook et al (1989) Molecular cloning: A laboratory Manual、第2版、コールド・スプリング・ハーバー・ラボラトリー・プレス、コールド・スプリング・ハーバー、ニューヨーク)。大腸菌DH5α株を、特別の定めのない限り、バイナリーベクターの増幅のための宿主に使用した。HA0遺伝子断片は、bglIIおよびSacIの制限部位を使用して、プラストシアニンカセット(既にpdiシグナルペプチドを含有する)の中へ直接ライゲーションされるか、またはKpnI、bglIIおよびSacI制限部位を使用して、7個の他のC末端とコライゲーションした。各々の事例において、遺伝子は、バイナリーベクターの転移DNA(t−DNA)上に含有されるプラストシアニン発現カセットの中へ挿入された。t−DNAは、形質転換に際して宿主植物細胞のゲノム(右境界から左境界)中に組込まれるバイナリーベクターの部分である。この実施例において使用されるバイナリーベクターは商業的プラスミドpCAMBIA 2300(キャンビア(Cambia)社、キャンベラ、オーストラリア)に由来し、t−DNAの右境界配列から左境界配列に以下のエレメントを含有する。
−rHA遺伝子が挿入されるウマゴヤシ属から利用可能な様々な専用発現カセット(プロモーターおよびターミネーター);
−クローニングを促進するマルチプルクローニング部位;および
−ノパリンシンターゼ(NOS)プロモーターおよびカリフラワー35Sモザイクウイルス(35S)ターミネーターの制御下のネオマイシンホスホトランスフェラーゼII(nptII)(カナマイシンに対する耐性を付与する選択可能なマーカー)についての遺伝子コード。
アグロバクテリウム増殖。rHA DNAコンストラクションを持つバイナリーベクターを含有するアグロバクテリウムクローン(表1)を、カルベニシリンおよびカナマイシンを各々25μg/mLおよび50μg/mLで含有する2mLのYEB培地またはLB培地中で28℃24時間でそれぞれ増殖させた。10μLのこれらの培養を出発接種物として使用して、YEB誘導培地(YEB培地、10mMの2(Nモルホリノ)エタンスルホン酸(MES)(pH5.6に調節)、25mg/Lカルベニシリン、50mg/Lカナマイシン、20μMアセトシリンゴン)の25mLの培養を生成した。後者は、28℃で18時間、または、0.8乃至1の600nmでの光学的密度(OD600)が達成されるまで、回転振盪機(220rpm)インキュベーター中で増殖させる。
接種した葉からの可溶性タンパク抽出物の調製。葉は、収穫後に直接、または−80℃でバイオマスを凍らせた後に分析した。〜0.1gのアグロ接種した葉の植物性バイオマスを秤量し、rHA一過性発現の解析のために使用した。
赤血球凝集試験。赤血球凝集分析は、本質的には、以下の修飾と共に、Nayak et al.(2004, J. Virol Methods, 122:9-15)によって記載されるように行なわれた。抽出物は、50mMトリスpH7.4、150mM NaCl、0.1%トリトンX−100、ならびにプロテアーゼ阻害剤としてPMSV 1MMおよびキモスタチン10μMを含有する中での組織のホモジナイゼーションによって調製された。可溶性画分をPBS中で0.2mg/mLに希釈した。サンプル(100μL)の連続的な二重希釈物は、100μLのPBSを含有する丸底の96ウェルマイクロプレート中で作製した。100μLのトリ赤血球(2×107rbc/mL)(イノベイティブ・リサーチ(Innovative Research)社、サウスフィールド、ミシガン、アメリカ)を、各々のウェルに追加した。次いでプレートを室温で60〜120分間インキュベーションした。分析は以下の陽性対照を含む。PBS中で希釈されるかまたは形質転換されていない抽出物中に添加される、1μg乃至7.8pgにわたるPSCからのrHA。形質転換されていない抽出物を使用する陰性対照も実行された。
本発明の一態様として、例えば以下のものがある。
〔1〕a)赤血球凝集素ドメインと;
b)オリゴマー化ドメインと
を含む組換え赤血球凝集素(rHA)であって、キメラ可溶性ホモ三量体として産生される、前記rHA。
〔2〕前記タンパク質がシグナルペプチドをさらに含む、前記〔1〕に記載のrHA。
〔3〕前記タンパク質が小胞体(ER)保留シグナルをさらに含む、前記〔1〕または〔2〕に記載のrHA。
〔4〕前記〔1〕乃至〔3〕のいずれか一項に記載のrHAをコードするヌクレオチド配列。
〔5〕a)赤血球凝集素ドメインをコードするヌクレオチド配列と;
b)オリゴマー化ドメインをコードするヌクレオチド配列と
を含む核酸配列であって、核酸がホモ三量体を形成する可溶性rHAをコードする、前記核酸配列。
〔6〕シグナルペプチドをコードするヌクレオチド配列をさらに含む、前記〔5〕に記載の核酸配列。
〔7〕小胞体(ER)保留シグナルをコードするヌクレオチド配列をさらに含む、前記〔5〕または〔6〕に記載の核酸。
〔8〕前記〔4〕乃至〔7〕のいずれか一項に記載のヌクレオチドを含むベクター。
〔9〕前記〔1〕乃至〔3〕のいずれか一項に記載のrHAを発現する宿主細胞。
〔10〕前記〔4〕乃至〔7〕のいずれか一項に記載のヌクレオチドにより形質転換された宿主細胞。
〔11〕前記〔8〕に記載のベクターにより形質転換された宿主細胞。
〔12〕組換えrHAタンパク質を産生する方法であって、
a)赤血球凝集素ドメインをコードするヌクレオチド配列と;
b)オリゴマー化ドメインをコードするヌクレオチド配列と
を含み、核酸がホモ三量体を形成する可溶性rHAをコードするベクターを、宿主細胞に提供することを含む、前記方法。
〔13〕植物内で組換え赤血球凝集素(rHA)を発現する方法であって、
a)赤血球凝集素ドメインをコードするヌクレオチド配列であって、核酸がホモ三量体を形成する可溶性rHAをコードするヌクレオチド配列と;
b)オリゴマー化ドメインをコードするヌクレオチド配列と
を含むベクターを、植物に導入すること、およびrHAを発現することを含む、前記方法。
〔14〕前記導入工程(工程a)において、前記核酸が一過性様式で前記植物中に導入される、前記〔13〕に記載の方法。
〔15〕前記導入工程(工程a)において、前記核酸が安定的に前記植物中に導入される、前記〔13〕に記載の方法。
〔16〕植物中で組換え赤血球凝集素(rHA)を産生する方法であって、
a)核酸配列を前記植物またはその一部に導入する工程であって、前記核酸配列が、赤血球凝集素ドメインおよびオリゴマー化ドメインをコードするヌクレオチド配列に作動可能に連結された制御領域を含み、核酸がホモ三量体を形成する可溶性rHAをコードする核酸配列である、前記工程と;
b)トランスジェニック植物を増殖させて、それによってrHAを産生する工程と
を含む、前記方法。
〔17〕前記導入工程(工程a)において、前記核酸が一過性様式で前記植物中に導入される、前記〔16〕に記載の方法。
〔18〕前記導入工程(工程a)において、前記核酸が安定的に前記植物中に導入される、前記〔16〕に記載の方法。
〔1’〕a)赤血球凝集素亜型H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、またはH16からなる群から選択される赤血球凝集素ドメインと;
b)GCN4−pIIペプチド、トウモロコシγ−ゼインのプロリンリッチドメイン(PRD)、及びバクテリオファージT4フィブリチンからなる群から選択されるオリゴマー化ドメインであって、該オリゴマー化ドメインがα−ヘリックスで終わらないようにC末端部にアミノ酸残基が加えられているオリゴマー化ドメインと;
c)プロテインジスルフィドイソメラーゼ(PDI)シグナルペプチドと
を含む組換え赤血球凝集素(rHA)であって、キメラ可溶性ホモ三量体として産生される、前記rHA。
〔2’〕前記加えられたアミノ酸残基が、Ser−Ala−Alaである、前記〔1’〕に記載のrHA。
〔3’〕小胞体(ER)保留シグナルをさらに含む、前記〔1’〕または〔2’〕に記載のrHA。
〔4’〕前記〔1’〕乃至〔3’〕のいずれか一項に記載のrHAをコードするヌクレオチド配列。
〔5’〕a)赤血球凝集素亜型H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、またはH16からなる群から選択される赤血球凝集素ドメインをコードするヌクレオチド配列と;
b)GCN4−pIIペプチド、トウモロコシγ−ゼインのプロリンリッチドメイン(PRD)、及びバクテリオファージT4フィブリチンからなる群から選択されるオリゴマー化ドメインであって、該オリゴマー化ドメインがα−ヘリックスで終わらないようにC末端部にアミノ酸残基が加えられているオリゴマー化ドメインをコードするヌクレオチド配列と;
c)プロテインジスルフィドイソメラーゼ(PDI)シグナルペプチドをコードするヌクレオチド配列と
を含む核酸であって、ホモ三量体を形成する可溶性rHAをコードする、前記核酸。
〔6’〕前記加えられるアミノ酸残基が、Ser−Ala−Alaである、前記〔5’〕に記載の核酸。
〔7’〕小胞体(ER)保留シグナルをコードするヌクレオチド配列をさらに含む、前記〔5’〕または〔6’〕に記載の核酸。
〔8’〕前記〔4’〕乃至〔7’〕のいずれか一項に記載の核酸を含むベクター。
〔9’〕前記〔1’〕乃至〔3’〕のいずれか一項に記載のrHAを発現する宿主細胞。
〔10’〕前記〔4’〕乃至〔7’〕のいずれか一項に記載の核酸により形質転換された宿主細胞。
〔11’〕前記〔8’〕に記載のベクターにより形質転換された宿主細胞。
〔12’〕組換え赤血球凝集素(rHA)を産生する方法であって、前記〔5’〕に記載の核酸を含む宿主細胞を提供すること、及び前記宿主細胞においてrHAを発現することを含む、前記方法。
〔13’〕植物内で組換え赤血球凝集素(rHA)を発現する方法であって、前記〔8’〕に記載のベクターを、植物に導入すること、およびrHAを発現することを含む、前記方法。
〔14’〕前記導入工程(工程a)において、前記核酸が一過性様式で前記植物中に導入される、前記〔13’〕に記載の方法。
〔15’〕前記導入工程(工程a)において、前記核酸が安定的に前記植物中に導入される、前記〔13’〕に記載の方法。
〔16’〕植物中で組換え赤血球凝集素(rHA)を産生する方法であって、
a)核酸配列を前記植物またはその一部に導入する工程であって、前記核酸配列が、前記〔5’〕に記載の核酸に作動可能に連結された制御領域を含む、前記工程と;
b)トランスジェニック植物を増殖させて、それによってrHAを産生する工程と
を含む、前記方法。
〔17’〕前記導入工程(工程a)において、前記核酸が一過性様式で前記植物中に導入される、前記〔16’〕に記載の方法。
〔18’〕前記導入工程(工程a)において、前記核酸が安定的に前記植物中に導入される、前記〔16’〕に記載の方法。
Claims (20)
- a)赤血球凝集素亜型H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、及びH16からなる群から選択される赤血球凝集素ドメインと;
b)GCN4−pIIペプチド、配列番号:2で示されるペプチドの4個、6個または8個のペプチド反復を含むトウモロコシγ−ゼインのプロリンリッチドメイン(PRD)、及びバクテリオファージT4フィブリチンからなる群から選択されるオリゴマー化ドメインであって、該オリゴマー化ドメインがα−ヘリックスで終わらないようにC末端部にアミノ酸残基が加えられているオリゴマー化ドメインと;
c)シグナルペプチドと;
d)小胞体(ER)保留シグナルと
を含む組換え赤血球凝集素(rHA)であって、キメラ可溶性ホモ三量体として産生される、前記rHA。 - 前記加えられたアミノ酸残基が、Ser−Ala−Alaである、請求項1に記載のrHA。
- 前記ER保留シグナルが、SEKDEL又はHDELである、請求項1又は2に記載のrHA。
- 前記シグナルペプチドが、プロテインジスルフィドイソメラーゼ(PDI)シグナルペプチドである、請求項1に記載のrHA。
- 請求項1乃至4のいずれか一項に記載のrHAをコードするヌクレオチド配列を含む核酸。
- a)赤血球凝集素亜型H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、及びH16からなる群から選択される赤血球凝集素ドメインをコードするヌクレオチド配列と;
b)GCN4−pIIペプチド、配列番号:2で示されるペプチドの4個、6個または8個のペプチド反復を含むトウモロコシγ−ゼインのプロリンリッチドメイン(PRD)、及びバクテリオファージT4フィブリチンからなる群から選択されるオリゴマー化ドメインであって、該オリゴマー化ドメインがα−ヘリックスで終わらないようにC末端部にアミノ酸残基が加えられているオリゴマー化ドメインをコードするヌクレオチド配列と; c)シグナルペプチドをコードするヌクレオチド配列と;
d)小胞体(ER)保留シグナルをコードするヌクレオチド配列と
を含む核酸であって、ホモ三量体を形成する可溶性組換え赤血球凝集素(rHA)をコードする、前記核酸。 - 前記加えられるアミノ酸残基が、Ser−Ala−Alaである、請求項6に記載の核酸。
- 前記ER保留シグナルが、SEKDEL又はHDELである、請求項6又は7に記載の核酸。
- 前記シグナルペプチドが、プロテインジスルフィドイソメラーゼ(PDI)シグナルペプチドである、請求項6に記載の核酸。
- 請求項5乃至9のいずれか一項に記載の核酸を含むベクター。
- 請求項1乃至4のいずれか一項に記載のrHAを発現する宿主細胞。
- 請求項5乃至9のいずれか一項に記載の核酸により形質転換された宿主細胞。
- 請求項10に記載のベクターにより形質転換された宿主細胞。
- 組換え赤血球凝集素(rHA)を産生する方法であって、請求項5乃至9のいずれか一項に記載の核酸を含む宿主細胞を提供すること、及び前記宿主細胞においてrHAを発現することを含む、前記方法。
- 植物内で組換え赤血球凝集素(rHA)を発現する方法であって、請求項10に記載のベクターを前記植物に導入すること、およびrHAを発現することを含む、前記方法。
- 前記導入工程において、前記核酸が一過性様式で前記植物中に導入される、請求項15に記載の方法。
- 前記導入工程において、前記核酸が安定的に前記植物中に導入される、請求項15に記載の方法。
- 植物中で組換え赤血球凝集素(rHA)を産生する方法であって、
a)核酸配列を前記植物またはその一部に導入する工程であって、前記核酸配列が、請求項5乃至9のいずれか一項に記載の核酸に作動可能に連結された制御領域を含む、前記工程と;
b)トランスジェニック植物を増殖させて、それによってrHAを産生する工程と
を含む、前記方法。 - 前記導入工程(工程a)において、前記核酸が一過性様式で前記植物中に導入される、請求項18に記載の方法。
- 前記導入工程(工程a)において、前記核酸が安定的に前記植物中に導入される、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7896308P | 2008-07-08 | 2008-07-08 | |
US61/078,963 | 2008-07-08 | ||
PCT/CA2009/000941 WO2010003235A1 (en) | 2008-07-08 | 2009-07-07 | Soluble recombinant influenza antigens |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011527181A JP2011527181A (ja) | 2011-10-27 |
JP2011527181A5 JP2011527181A5 (ja) | 2012-08-23 |
JP5809054B2 true JP5809054B2 (ja) | 2015-11-10 |
Family
ID=41506627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011516935A Active JP5809054B2 (ja) | 2008-07-08 | 2009-07-07 | 可溶性組換えインフルエンザ抗原 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8771703B2 (ja) |
EP (1) | EP2294202B1 (ja) |
JP (1) | JP5809054B2 (ja) |
CN (2) | CN105753948A (ja) |
AU (1) | AU2009267769B2 (ja) |
CA (1) | CA2730171C (ja) |
DK (1) | DK2294202T3 (ja) |
ES (1) | ES2545607T3 (ja) |
HK (1) | HK1154041A1 (ja) |
PT (1) | PT2294202E (ja) |
WO (1) | WO2010003235A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
EP2413962A1 (en) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
KR20180026562A (ko) | 2009-09-22 | 2018-03-12 | 메디카고 인코포레이티드 | 식물-유래 단백질의 제조방법 |
EP2536425B1 (en) | 2010-02-18 | 2019-06-19 | Icahn School of Medicine at Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
KR20130075732A (ko) | 2010-03-30 | 2013-07-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
WO2012011868A1 (en) * | 2010-07-23 | 2012-01-26 | Osterhaus A D M E | Influenza vaccine |
JP2013542928A (ja) * | 2010-09-30 | 2013-11-28 | フランバックス ソチエタ レスポンサビリタ リミテ | ビロソーム粒子の生成 |
TWI526539B (zh) | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
WO2012117045A1 (en) * | 2011-03-02 | 2012-09-07 | Intervet International B.V. | Infectious bronchitis virus (ibv) spike protein as subunit vaccine |
TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
EP2758075B1 (en) * | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
US11390878B2 (en) | 2011-09-30 | 2022-07-19 | Medicago Inc. | Increasing protein yield in plants |
US11155581B2 (en) | 2011-09-30 | 2021-10-26 | Medicago Inc. | Increasing virus-like particle yield in plants |
AU2013362935B2 (en) | 2012-12-18 | 2018-10-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
CN105247059B (zh) | 2013-03-28 | 2021-07-06 | 莫迪卡戈公司 | 植物中流感样病毒颗粒的产生 |
US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
TW201731865A (zh) * | 2016-03-15 | 2017-09-16 | 國立清華大學 | 重組h7血凝素及其應用 |
WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
US11529413B2 (en) | 2018-06-12 | 2022-12-20 | Kbio Holdings Limited | Virus and antigen purification and conjugation |
US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
KR20210010888A (ko) * | 2018-06-12 | 2021-01-28 | 켄터키 바이오프로세싱 인코포레이티드 | 바이러스 및 항원 정제 및 접합 |
US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US20230203101A1 (en) * | 2020-04-22 | 2023-06-29 | POSTECH Research and Business Development Foundation | Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof |
WO2021249013A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Vaccine compositions, methods, and uses thereof |
CN111662390A (zh) * | 2020-06-17 | 2020-09-15 | 天康生物(上海)有限公司 | 禽流感HA-Fd融合蛋白及其制备方法和疫苗 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986003224A1 (en) | 1984-11-29 | 1986-06-05 | Scripps Clinic And Research Foundation | Polypeptides and antibodies related to deglycosylated viral glycoproteins |
US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
ATE142883T1 (de) | 1991-03-28 | 1996-10-15 | Rooperol Na Nv | Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
GB9409768D0 (en) | 1994-05-16 | 1994-07-06 | Medical Res Council | Trimerising polypeptides |
WO1998056906A1 (en) | 1997-06-11 | 1998-12-17 | Thoegersen Hans Christian | Trimerising module |
US20010006950A1 (en) | 1998-02-11 | 2001-07-05 | Juha Punnonen | Genetic vaccine vector engineering |
US6489537B1 (en) | 1998-08-07 | 2002-12-03 | The Trustees Of The University Of Pennsylvania | Phytochelatin synthases and uses therefor |
DE69933677T2 (de) | 1998-08-11 | 2007-08-23 | Biosource Technologies, Inc., Vacaville | Verfahren zur gewinnung von proteinen aus der interstitiellen flüssigkeit von pflanzen |
WO2000020557A2 (en) | 1998-10-07 | 2000-04-13 | Boyce Institute For Plant Research At Cornell University | Gemini virus vectors for gene expression in plants |
FR2791358B1 (fr) | 1999-03-22 | 2003-05-16 | Meristem Therapeutics | Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
DE60232577D1 (de) * | 2001-01-18 | 2009-07-23 | Vlaams Interuniv Inst Biotech | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential |
US7226774B2 (en) | 2002-02-13 | 2007-06-05 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
NZ534881A (en) | 2002-03-19 | 2006-09-29 | Plant Res Internat B | Mammalian GnTIII expression in plants |
ES2224792B1 (es) * | 2002-06-28 | 2007-02-16 | Era Plantech, S.L. | Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas. |
AU2004235800B2 (en) | 2003-05-05 | 2010-02-18 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
ZA200508930B (en) | 2003-05-05 | 2007-03-28 | Thompson Boyce Inst Plant Research | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
ES2662118T3 (es) | 2005-04-29 | 2018-04-05 | University Of Cape Town | Expresión de proteínas virales en las plantas |
CA2615658A1 (en) | 2005-07-19 | 2007-01-25 | Dow Global Technolgies Inc. | Recombinant flu vaccines |
US20070042002A1 (en) * | 2005-08-16 | 2007-02-22 | Hawaii Biotech, Inc. | Influenza recombinant subunit vaccine |
SI1937301T1 (sl) | 2005-10-18 | 2015-08-31 | Novavax, Inc. | Funkcionalni influenčnemu virusu podobni delci (VLP) |
AU2007215080A1 (en) | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Influenza antigens, vaccine compositions, and related methods |
CA2650091A1 (en) | 2006-04-21 | 2008-05-22 | Dow Agrosciences Llc | Vaccine for avian influenza and methods of use |
US8778353B2 (en) | 2006-05-01 | 2014-07-15 | Technovax, Inc. | Influenza virus-like particle (VLP) compositions |
CA2657849A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
US20070286873A1 (en) | 2006-05-23 | 2007-12-13 | Williams John V | Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor |
PT2155880T (pt) | 2007-06-15 | 2016-11-18 | Medicago Inc | Modificação da produção de glicoproteína em plantas |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
US20110059130A1 (en) | 2007-08-20 | 2011-03-10 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods |
CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
GB0800272D0 (en) | 2008-01-08 | 2008-02-13 | Plant Bioscience Ltd | Protein expression systems |
KR101956910B1 (ko) | 2008-01-21 | 2019-03-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs) |
DE102008009491B4 (de) | 2008-02-15 | 2010-02-04 | Rainer Brenner | Vorrichtung zur Sicherung von Waren |
DK2318530T3 (en) | 2008-07-18 | 2016-10-03 | Medicago Inc | Ny epitope to immunization against influenza |
US8513397B2 (en) | 2008-08-27 | 2013-08-20 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants |
WO2010077712A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
-
2009
- 2009-07-07 WO PCT/CA2009/000941 patent/WO2010003235A1/en active Application Filing
- 2009-07-07 CA CA2730171A patent/CA2730171C/en active Active
- 2009-07-07 ES ES09793751.0T patent/ES2545607T3/es active Active
- 2009-07-07 EP EP09793751.0A patent/EP2294202B1/en active Active
- 2009-07-07 US US13/001,111 patent/US8771703B2/en active Active
- 2009-07-07 PT PT97937510T patent/PT2294202E/pt unknown
- 2009-07-07 AU AU2009267769A patent/AU2009267769B2/en active Active
- 2009-07-07 CN CN201610265015.XA patent/CN105753948A/zh active Pending
- 2009-07-07 JP JP2011516935A patent/JP5809054B2/ja active Active
- 2009-07-07 DK DK09793751.0T patent/DK2294202T3/en active
- 2009-07-07 CN CN200980126670.5A patent/CN102089432A/zh active Pending
-
2011
- 2011-08-04 HK HK11108155.1A patent/HK1154041A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1154041A1 (en) | 2012-04-13 |
US8771703B2 (en) | 2014-07-08 |
CN105753948A (zh) | 2016-07-13 |
CN102089432A (zh) | 2011-06-08 |
WO2010003235A1 (en) | 2010-01-14 |
JP2011527181A (ja) | 2011-10-27 |
CA2730171A1 (en) | 2010-01-14 |
AU2009267769A1 (en) | 2010-01-14 |
AU2009267769B2 (en) | 2015-07-16 |
EP2294202B1 (en) | 2015-05-20 |
PT2294202E (pt) | 2015-10-09 |
EP2294202A1 (en) | 2011-03-16 |
CA2730171C (en) | 2016-10-11 |
US20110104753A1 (en) | 2011-05-05 |
ES2545607T3 (es) | 2015-09-14 |
DK2294202T3 (en) | 2015-08-31 |
EP2294202A4 (en) | 2011-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5809054B2 (ja) | 可溶性組換えインフルエンザ抗原 | |
Firsov et al. | High-yield expression of M2e peptide of avian influenza virus H5N1 in transgenic duckweed plants | |
JP6038041B2 (ja) | ウイルス様粒子の植物における産生 | |
US9546375B2 (en) | Influenza virus immunizing epitope | |
TR201802091T4 (tr) | Bitkilerde rotavirüs - benzeri partikül üretimi. | |
JP2024050650A (ja) | インフルエンザウイルスヘマグルチニン変異体 | |
WO2024040325A1 (en) | Modified influenza b virus hemagglutinin | |
AU2015202195A1 (en) | New influenza virus immunizing epitope | |
Plants | Aleksey Firsov, Irina Tarasenko, Tatiana Mitiouchkina, Natalya Ismailova, Lyubov Shaloiko, Alexander Vainstein & Sergey Dolgov |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140404 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140507 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150624 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150817 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150910 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5809054 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |